JP2016510787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510787A5 JP2016510787A5 JP2015562144A JP2015562144A JP2016510787A5 JP 2016510787 A5 JP2016510787 A5 JP 2016510787A5 JP 2015562144 A JP2015562144 A JP 2015562144A JP 2015562144 A JP2015562144 A JP 2015562144A JP 2016510787 A5 JP2016510787 A5 JP 2016510787A5
- Authority
- JP
- Japan
- Prior art keywords
- crizotinib
- lubricant
- tablet
- optionally
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 13
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 8
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 8
- 229960005061 crizotinib Drugs 0.000 claims 8
- 239000000314 lubricant Substances 0.000 claims 8
- 239000012458 free base Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780015P | 2013-03-13 | 2013-03-13 | |
| US61/780,015 | 2013-03-13 | ||
| EP13001257 | 2013-03-13 | ||
| EP13001257.8 | 2013-03-13 | ||
| PCT/EP2014/054933 WO2014140159A1 (en) | 2013-03-13 | 2014-03-13 | Dosage form comprising crizotinib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016510787A JP2016510787A (ja) | 2016-04-11 |
| JP2016510787A5 true JP2016510787A5 (cg-RX-API-DMAC7.html) | 2017-04-13 |
Family
ID=47900469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562144A Pending JP2016510787A (ja) | 2013-03-13 | 2014-03-13 | クリゾチニブを含む剤形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160022661A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2968167A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016510787A (cg-RX-API-DMAC7.html) |
| EA (1) | EA201591644A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014140159A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721243B (zh) * | 2017-04-25 | 2022-07-08 | 正大天晴药业集团股份有限公司 | 克唑替尼药物组合物及其制备方法 |
| US20230338380A1 (en) * | 2019-12-31 | 2023-10-26 | Pfizer R&D Uk Limited | Stable Immediate Release Tablet and Capsule Formulations of 1-((2S,5R)-5-((7H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino)-2-Methylpiperidin-1-YL)Prop-2-EN-1-One |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| NZ568654A (en) * | 2005-12-05 | 2012-02-24 | Pfizer Prod Inc | Method of treating abnormal cell growth |
| DE102009015702A1 (de) * | 2009-03-31 | 2010-10-07 | Ratiopharm Gmbh | Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung |
-
2014
- 2014-03-13 US US14/774,072 patent/US20160022661A1/en not_active Abandoned
- 2014-03-13 EP EP14709950.1A patent/EP2968167A1/en not_active Withdrawn
- 2014-03-13 EA EA201591644A patent/EA201591644A1/ru unknown
- 2014-03-13 JP JP2015562144A patent/JP2016510787A/ja active Pending
- 2014-03-13 WO PCT/EP2014/054933 patent/WO2014140159A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015155711A4 (en) | Immunosuppressant formulation | |
| JP2017510602A5 (cg-RX-API-DMAC7.html) | ||
| JP2018534348A5 (cg-RX-API-DMAC7.html) | ||
| PH12017502325B1 (en) | Orodispersible dosage unit containing an estetrol component | |
| PH12017502326B1 (en) | Orodispersible dosage unit containing an estetrol component | |
| JP2016528302A5 (cg-RX-API-DMAC7.html) | ||
| MX386413B (es) | Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk. | |
| JP2015110674A5 (cg-RX-API-DMAC7.html) | ||
| JP2015511635A5 (cg-RX-API-DMAC7.html) | ||
| RU2015102553A (ru) | Фармацевтическая композиция, содержащая фимасартан и гидрохлортиазид | |
| JP2014205701A5 (cg-RX-API-DMAC7.html) | ||
| MY186229A (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
| MX2023006856A (es) | Composiciones de polvo seco con estearato de magnesio. | |
| CN109641851A (zh) | 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途 | |
| JP2009542678A5 (cg-RX-API-DMAC7.html) | ||
| JP2017502948A5 (cg-RX-API-DMAC7.html) | ||
| WO2020127819A3 (en) | Pharmaceutical composition comprising apixaban | |
| JP2014518226A5 (cg-RX-API-DMAC7.html) | ||
| JP2016510787A5 (cg-RX-API-DMAC7.html) | ||
| JP2015120758A5 (cg-RX-API-DMAC7.html) | ||
| JP2017520619A5 (cg-RX-API-DMAC7.html) | ||
| EP3860606A1 (en) | Pharmaceutical composition comprising lenvatinib esylate or tosylate | |
| RU2015129714A (ru) | Композиция в форме таблеток, содержащая гидрохлорид цинакалцета | |
| WO2015119924A3 (en) | Fixed-dose combinations of antiviral compounds | |
| MX2017015322A (es) | Composicion farmaceutica oral de isotretinoin. |